25.05
Flexion Therapeutics, Inc. 주식(FLXN)의 최신 뉴스
Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill
Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com
Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com
Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal
Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - Akin
Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Intra-Articular Injections Market Size to Hit USD 13.65 Billion by 2035 - Precedence Research
Joint Pain Injections Market Overview and Leading Players: - openPR.com
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - BioSpace
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
Knee Osteoarthritis Treatment Market Size, Share | CAGR Of 7.7% - Market.us
Knee Osteoarthritis Injectable Treatments Market Size to Hit USD 6.78 Billion by 2035 - Precedence Research
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Appoints Dr. William T. Andrews as Chief Medical Officer | CPRX Stock News - Quiver Quantitative
Anti-Inflammatory Therapeutics Market Size, Value & Trends | By 2033 - Straits Research
Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest Technology
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer - GlobeNewswire
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Osteoarthritis Treatment Market 2032: FDA Approvals, Clinical - openPR.com
Pacira BioSciences Reports Second Quarter 2024 Financial Results - GlobeNewswire
Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as Chief Medical Officer - citybiz
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Ocular Therapeutix Appoints Steve Meyers as Chief Commercial Officer - citybiz
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire
Is Osteoarthritis Cure — ARPA-H NITRO — Rocket Fuel Or TNT? - Clinical Leader
Joint Pain Injections Market Strategic Market Study 2033 - SkyQuest Technology Consulting
Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal Disorders - Docwire News
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic - PR Newswire
Global Joint Pain Injections Market Size & Share Revenue Is - GlobeNewswire
Osteoarthritis Therapeutics Market Size | Forecast [2033] - SkyQuest Technology
Versant Development Fund Iii, L.p. Net Worth (2026) - GuruFocus
Utpal Koppikar named Alphabet health firm Verily CFO - The American Bazaar
Indian American Utpal Koppikar Named CFO of Alphabet Precision Health Company Verily - American Kahani
Insights on the Osteoarthritis Therapeutics Global Market to 2027Easy Access to MRI Scans Drives Growth - GlobeNewswire
Anti-Inflammatory Therapeutics Market Size To Hold USD 127.5 Bn By 2030 - BioSpace
자본화:
|
볼륨(24시간):